End tuberculosis by 2035: challenges ahead

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. WHO. Global Tuberculosis Report 2022 (2022). www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
  Google Scholar
• 2. Shariq M, Sheikh JA, Quadir N et al. COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur. Respir. Rev. 31(164), 210264 (2022). •• Describes how two respiratory diseases can have a larger impact on human health and how one pandemic can be detrimental to fighting other pandemics.
  MedlineGoogle Scholar
• 3. Chakaya J, Khan M, Ntoumi F et al. Global Tuberculosis Report 2020 – reflections on the global TB burden, treatment and prevention efforts. Int. J. Infect. Dis. 113(Suppl. 1), S7–S12 (2021). • Considers the global tuberculosis (TB) burden, with the importance of future research.
  Medline CASGoogle Scholar
• 4. Abidi S, Achar J, Assao Neino MM et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur. Respir. J. 55(3), 1901467 (2020). • This article is of interest as it reflects upon the shortening of TB regimens, while comparing it to individualized regimens which can be of greater importance in treating drug-resistant TB.
  Medline CASGoogle Scholar
• 5. Chakaya JM, Marais B, du Cros P et al. Programmatic versus personalised approaches to managing the global epidemic of multidrug-resistant tuberculosis. Lancet Respir. Med. 8(4), 334–335 (2020).
  Medline CASGoogle Scholar
• 6. Pandey V, Singh P, Singh S et al. SeeTB: a novel alternative to sputum smear microscopy to diagnose tuberculosis in high burden countries. Sci. Rep. 9(1), 16371 (2019). • Discusses the novel and cost-effective diagnosis of TB,
  MedlineGoogle Scholar
• 7. Sanchez-Padilla E, Merker M, Beckert P et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N. Engl. J. Med. 372(12), 1181–1182 (2015).
  Medline CASGoogle Scholar
• 8. Parwati CG, Farid MN, Nasution HS et al. Estimation of subnational tuberculosis burden: generation and application of a new tool in Indonesia. Int. J. Tuberc. Lung Dis. 24(2), 250–257 (2020).
  Medline CASGoogle Scholar
• 9. Subbaraman R, Nathavitharana RR, Mayer KH et al. Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care. PLoS Med. 16(2), e1002754 (2019).
  MedlineGoogle Scholar
• 10. Ignatius EH, Cohen KA, Bishai WR. Getting to the point in point-of-care diagnostics for tuberculosis. J. Clin. Invest. 130(11), 5671–5673 (2020).
  Medline CASGoogle Scholar
• 11. Shaku MT, Bishai WR. Mycobacterium tuberculosis: a pathogen that can hold its breath a long time. Am. J. Respir. Crit. Care Med. 206(1), 10–12 (2022). • Focuses on an intricate conundrum in TB diagnosis and prevalence and the role of latent tuberculosis.
  MedlineGoogle Scholar
• 12. Behr MA, Edelstein PH, Ramakrishnan L. Is Mycobacterium tuberculosis infection life long? BMJ 367, l5770 (2019).
  MedlineGoogle Scholar
• 13. Conradie F, Bagdasaryan TR, Borisov S et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med. 387(9), 810–823 (2022). •• Explains how combined antitubercular drugs show positive results against drug-resistant tuberculosis.
  Medline CASGoogle Scholar
• 14. Singh J, Rahman SA, Ehtesham NZ et al. SARS-CoV-2 variants of concern are emerging in India. Nat. Med. 27(7), 1131–1133 (2021).
  Medline CASGoogle Scholar
• 15. Sheikh JA, Ehtesham NZ, Hasnain SE. Revisiting BCG to control tuberculosis: mucosal delivery and delipidation? Lancet Infect. Dis. 20(3), 272–273 (2020). •• Of considerable interest because bacille Calmette-Guérin has already been a cornerstone in immunization against TB. To understand how it can be modulated for better efficacy, especially in adults and via different routes, could play a major role in the end-TB strategy.
  MedlineGoogle Scholar
• 16. Harris RC, Quaife M, Weerasuriya C et al. Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India. Nat. Commun. 13, 602 (2022). •• Of considerable interest because the advent of an effective vaccine may be the ‘final nail in the coffin’ for TB.
  Medline CASGoogle Scholar
• 17. Coleman J. Eight countries eliminated a neglected tropical disease in 2022. Nature doi.org/10.1038/d41586-023-00286-9 (2023) (Epub ahead of print).
  Google Scholar